Ide-Cel Shows Durable Response in R/R Multiple Myeloma: Larry D. Anderson, Jr, MD, PhD

Video

The hematologist/oncologist from the Harold C. Simmons Comprehensive Cancer Center discussed the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

This content originally appeared on our sister site, Targeted Oncology.

Targeted Oncology spoke with Larry D. Anderson, Jr, MD, PhD, hematologist/oncologist, Harold C. Simmons Comprehensive Cancer Center and associate professor, Division of Hematology/Oncology, Department of Internal Medicine, UT Southwestern Medical Center, about the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

Long-term data for idecabtagene vicleucel (ide-cel, bb2121) demonstrated deep and durable remissions in a majority of patients on the trial, according to Anderson. Patients with relapsed/refractory multiple myeloma on this trial had a median of 6 prior lines of therapy. With a median 24.8-month follow-up, the median overall survival on trial was 24.8 months also. For the 128 patients, there was a 73% overall response rate, and the median progression-free survival (PFS) was 8.6 months. Those who received the target dose of 450 million chimeric antigen receptor T cells had a median PFS of 12.2 months.

Anderson says another notable topic was the FDA label for ide-cel requires patients to have 4 prior lines of therapy while the trial only required 3 prior lines of therapy. One of the study analyses looked at efficacy for patients who received 3 prior lines versus 4 or more. There was not a significant difference in outcomes for these 2 groups.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.